Research programme: cyanoaziridine derivatives - Amplimed
Alternative Names: AMP423; Cyanoaziridine anti-cancer therapies; CyanoaziridinesLatest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator AmpliMed
- Class Aziridines; Small molecules
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 28 Apr 2011 Preclinical development is ongoing in USA
- 06 Apr 2011 Pharmacodynamics data from a preclinical trial in Cancer presented at the 102nd Annual Meeting of the American Association for Cancer Research (102nd-AACR-2011)